ReviewDiagnostics (Basel, Switzerland)2020
Diagnosis and Management of Acute Respiratory Distress Syndrome in a Time of COVID-19.
Review in Diagnostics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Catalase: A Potential Pharmacologic Target for Hydrogen Peroxide in the Treatment of COVID-19.Current topics in medicinal chemistry · 2024Pooled it
- The Critical Role of Steroid Regimen for Lung Repair in Experimental Diffuse Alveolar Damage.International journal of molecular sciences · 2026Article
- Characteristics and temporality of the ventilatory techniques in the management of acute respiratory distress syndrome: A scoping review.Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) · 2025Review
- The Novel Effect and Potential Mechanism of Lactoferrin on Organ Fibrosis Prevention.Nutrients · 2025Review
- Experimental animal models of acute respiratory distress syndrome: one-hit and two-hit establishment application.Frontiers in immunology · 2025Review
- Understanding Causes of Death in Patients With Acute Respiratory Distress Syndrome: A Narrative Review.Critical care explorations · 2024Review
- Self-assembled carbon monoxide nanogenerators managing sepsis through scavenging multiple inflammatory mediators.Bioactive materials · 2024Article
- Prediction of COVID-19 Hospitalization and Mortality Using Artificial Intelligence.Healthcare (Basel, Switzerland) · 2024Article
- Comparison of Ventilator Mechanics and Mortality Between COVID-19 Versus Non-COVID-19 Acute Respiratory Distress Syndrome Patients: A Cross-Sectional Study.Journal of acute medicine · 2023Article
- Insights into COVID-19-associated critical illness: a narrative review.Annals of translational medicine · 2023Review
- Proteomic analysis and identification reveal the anti-inflammatory mechanism of clofazimine on lipopolysaccharide-induced acute lung injury in mice.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022Article
- Timing and Outcomes of Noninvasive Ventilation in 307 ARDS COVID-19 Patients: An Observational Study in an Italian Third Level COVID-19 Hospital.Medicina (Kaunas, Lithuania) · 2022Observational
- A narrative review of COVID-19-related acute respiratory distress syndrome (CARDS): "typical" or "atypical" ARDS?Annals of translational medicine · 2022Review
- A German AWMF's S2e/realist synthesis and meta-narrative snapshot of craniomaxillofacial manifestations in COVID-19 patients: Rapid living update on 1 January 2021.Journal of stomatology, oral and maxillofacial surgery · 2022Review
- Acute Respiratory Distress Syndrome: Focus on Viral Origin and Role of Pulmonary Lymphatics.Biomedicines · 2021Review
- Current Potential Therapeutic Approaches against SARS-CoV-2: A Review.Biomedicines · 2021Review
- Cytokine Drizzle-The Rationale for Abandoning "Cytokine Storm".Shock (Augusta, Ga.) · 2021Review
- COVID-19 influences lung microbiota dynamics and favors the emergence of rare infectious diseases: A case report of Hafnia Alvei pneumonia.Journal of critical care · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute respiratory distress syndrome (ARDS) remains a serious illness with significant morbidity and mortality, characterized by hypoxemic respiratory failure most commonly due to pneumonia, sepsis, and aspiration. Early and accurate diagnosis of ARDS depends upon clinical suspicion and chest imaging. Coronavirus disease 2019 (COVID-19) is an important novel cause of ARDS with a distinct time course, imaging and laboratory features from the time of SARS-CoV-2 infection to hypoxemic respiratory failure, which may allow diagnosis and management prior to or at earlier stages of ARDS. Treatment of ARDS remains largely supportive, and consists of incremental respiratory support (high flow nasal oxygen, non-invasive respiratory support, and invasive mechanical ventilation), and avoidance of iatrogenic complications, all of which improve clinical outcomes. COVID-19-associated ARDS is largely similar to other causes of ARDS with respect to pathology and respiratory physiology, and as such, COVID-19 patients with hypoxemic respiratory failure should typically be managed as other patients with ARDS. Non-invasive respiratory support may be beneficial in avoiding intubation in COVID-19 respiratory failure including mild ARDS, especially under conditions of resource constraints or to avoid overwhelming critical care resources. Compared to other causes of ARDS, medical therapies may improve outcomes in COVID-19-associated ARDS, such as dexamethasone and remdesivir. Future improved clinical outcomes in ARDS of all causes depends upon individual patient physiological and biological endotyping in order to improve accuracy and timeliness of diagnosis as well as optimal targeting of future therapies in the right patient at the right time in their disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.